Coronavirus – WHO approves two new drugs to treat corona patients – Belgium

(Belga) The World Health Organization WHO has approved two new drugs for the treatment of corona patients. These are baricitinib and sotrovimab.

The drug baricitinib, which has been used to treat rheumatism patients, is strongly recommended in combination with corticosteroids for patients with severe COVID-19, a WHO publication in the medical journal The BMJ said. That strong recommendation is based on evidence that it improves survival and reduces the need for extra ventilation. The WHO experts also point out that baricitinib works in the same way as interleukin-6 receptor blockers, which have already received a positive recommendation from the World Health Organization. A choice between the two means must be made on the basis of cost and availability. The WHO does not recommend using both drugs at the same time. In addition, the WHO also recommends the use of the monoclonal antibody sotrovimab. There, the World Health Organization recommends its use in patients who do not have severe COVID-19, albeit only in patients at the highest risk of hospitalization. Previously, the WHO gave the green light to the monoclonal antibody casirivimab-imdevimab. The new recommendations are based on seven studies involving a total of 4,000 COVID patients. (Belgium)

The drug baricitinib, which has been used to treat rheumatism patients, is strongly recommended in combination with corticosteroids for patients with severe COVID-19, a WHO publication in the medical journal The BMJ said. That strong recommendation is based on evidence that it improves survival and reduces the need for extra ventilation. The WHO experts also point out that baricitinib works in the same way as interleukin-6 receptor blockers, which have already received a positive recommendation from the World Health Organization. A choice between the two means must be made on the basis of cost and availability. The WHO does not recommend using both drugs at the same time. In addition, the WHO also recommends the use of the monoclonal antibody sotrovimab. There, the World Health Organization recommends its use in patients who do not have severe COVID-19, albeit only in patients at the highest risk of hospitalization. Previously, the WHO gave the green light to the monoclonal antibody casirivimab-imdevimab. The new recommendations are based on seven studies involving a total of 4,000 COVID patients. (Belgium)

Leave a Comment